Scientific Programme

19th Annual ENETS Conference

Took place as a hybrid event on 10 - 11 March 2022

in Barcelona, Spain

Programme

10 - 11 March 2022 - Hybrid Event

Thursday, 10 March 2022

Welcome

Time: Thursday 08:30 - 08:40
Marianne Pavel, GER /

Opening session: Are we ready for precision medicine in NEN in 2022?

Time: Thursday 08:40 - 09:00
James Yao, USA /

Session 1: Molecular pathology and precision medicine

Time: Thursday 09:00 - 10:30
Chairs: Anne Couvelard, FRA / Enrique Grande, ESP /
09:00 - 09:05 Introduction
Anne Couvelard, FRA /
09:05 - 09:20 Theranostic markers in well differentiated NET
Thomas Walter, FRA /
09:20 - 09:35 Theranostic markers in NEC
Halfdan Sorbye, NOR /
09:35 - 09:55 Panel discussion
09:55 - 10:02 Abstract presentation: Molecular characterization of a multi-institutional pan-lung cohort using integrative genomic and transcriptomic analysis
Michele Simbolo, ITA /
10:02 - 10:07 Discussion
10:08 - 10:15 Abstract presentation: Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: The Gustave Roussy experience
Alice Boilève, FRA /
10:15 - 10:20 Discussion
10:20 - 10:30 Putting molecular profiling into perspective
Jaume Capdevila, ESP /

Coffee break

Time: Thursday 10:30 - 11:00

Session 2A: New developments in nuclear medicine

Time: Thursday 11:00 - 12:15
Chairs: Vikas Prasad, GER / Irene Virgolini, AUT /
11:00 - 11:15 Moving beyond RECIST-PFS for assessment of outcome after PRRT
Martyn Caplin, GBR /
11:15 - 11:20 Discussion
11:20 - 11:35 Integration of functional imaging and molecular pathology for optimal treatment selection in NEN
Grace Kong, AUS /
11:35 - 11:40 Discussion
11:40 - 11:55 Modulation of targets for increasing the efficacy of PRRT
Wolfgang Weber, GER /
11:55 - 12:00 Discussion
12:00 - 12:10 Abstract presentation: Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy
Esben Andreas Carlsen, DEN /
12:10 - 12:15 Discussion

Session 2B: Best abstracts - Clinical Science

Time: Thursday 11:00 - 12:15
Chairs: Wouter W. De Herder, NED / Simron Singh, CAN /
11:00 - 11:07 Molecular Imaging Tumor Volume of Somatostatin Receptor (MITVSSR) on 68Ga-DOTATATE PET/CT, dosimetry and predictors of overall survival and response in unresectable neuroendocrine neoplasms treated with PRRT
Ramin Alipour, AUS /
11:07 - 11:12 Discussion
11:12 - 11:19 Risk of myelodysplastic syndrome/acute leukemia with sequential capecitabine/temozolomide and 177Lu-dotatate
Taymeyah Al-Toubah, USA /
11:19 - 11:24 Discussion
11:24 - 11:31 Prognostic factors for progression-free survival (PFS) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study
Eric Baudin, FRA /
11:31 - 11:36 Discussion
11:36 - 11:43 Effect of lanreotide autogel/depot (LAN) on tumor growth rate (TGR) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study
Jaume Capdevila, ESP /
11:43 - 11:48 Discussion
11:48 - 11:55 Nodal recurrence after curative surgery for non-functioning pancreatic neuroendocrine tumors: A retrospective cohort study
Valentina Andreasi, POR /
11:55 - 12:00 Discussion
12:00 - 12:07 Minimally invasive laparoscopic and robotic versus open hepatic resection for NEN liver metastasis: Case matched study with propensity score matching
Andreas Pascher, GER /
12:07 - 12:15 Discussion

Lunch break

Time: Thursday 12:30 - 14:00

Satellite symposium – Industry-sponsored

Time: Thursday 12:30 - 14:00

Session 3A: Defining success and individualising therapy in NEN

Time: Thursday 14:00 - 15:15
Chairs: Dermot O'Toole, IRL / John Ramage, GBR /
14:00 - 14:10 What is the most appropriate outcome for quality-of-life measurements in trials and daily practice?
Espen Thiis-Evensen, NOR /
14:10 - 14:20 Individualised treatment strategies
Simron Singh, CAN /
14:20 - 14:30 Long term sequelae versus toxicity
Eric Baudin, FRA /
14:30 - 14:40 Patient engagement in treatment decisions
Catherine Bouvier, GBR /
14:40 - 14:50 Patient and caregiver NET lives / story
Michael Rosenberg, ISR /
14:50 - 15:15 Discussion

Session 3B: Best abstracts – Preclinical science

Time: Thursday 14:00 - 15:15
Chairs: Kjell Öberg, SWE / Aurel Perren, SUI /
14:00 - 14:07 Metabolomic profile of extra-pancreatic NET: A novel prognostic tool?
Anna La Salvia, ESP /
14:07 - 14:12 Discussion
14:12 - 14:19 Comparative biocomputational analysis of the splicing landscape across lung neuroendocrine neoplasms unveils a new actionable molecular layer
Ricardo Blázquez-Encinas, ESP /
14:19 - 14:24 Discussion
14:24 - 14:31 Cancer associated fibroblasts induce proliferation and therapeutic resistance in neuroendocrine tumors through STAT3 activation
Tania Amin, GER /
14:31 - 14:36 Discussion
14:36 - 14:43 Longitudinal copy number alteration analysis in plasma cell-free DNA of neuroendocrine neoplasms is a novel specific biomarker for diagnosis, prognosis and follow-up
Laura Mariën, BEL /
14:43 - 14:48 Discussion
14:48 - 14:55 Comparison of drug sensitivity profiles of various NEN spheroids
Po Hien Ear, USA /
14:55 - 15:00 Discussion
15:00 - 15:07 Patient-derived tumoroids phenocopy original gastro-entero-pancreatic neuroendocrine neoplasms and facilitate in vitro drug screening
Simon April-Monn, SUI /
15:07 - 15:15 Discussion

Coffee break

Time: Thursday 15:15 - 15:40

Session 4A: Joint session: European Society of Surgical Oncology (ESSO) / ENETS

Time: Thursday 15:40 - 17:05
Chairs: Detlef Klaus Bartsch, GER / Rocio Garcia-Carbonero, ESP / Stefan Stättner, AUT /
PART 1 (15:40 - 16:20)
15:40 - 15:55 A message from the ESSO president: Surgical oncology and NEN disease – Does one size fit all?
Domenico D'Ugo, ITA /
15:55 - 16:00 Discussion
16:00 - 16:15 Trust the surgeon – Individual approaches and outcomes of pancreatic surgery
Els Nieveen van Dijkum, NED /
16:15 - 16:20 Discussion
PART 2: Surgery with curative intent to liver dominant disease – What is the number one choice? (16:20 - 17:05)
16:20 - 16:30 The surgeon: Resection is king / Direct visibility / Regenerative potential and safe techniques
Michel Rivoire, FRA /
16:30 - 16:40 The interventional radiologist: (Stereotactic) ablation does better than any surgical approach
Reto Bale, AUT /
16:40 - 16:50 The transplant surgeon: Extended donor criteria will push transplantation to treatment of choice
Cristina Dopazo, ESP /
16:50 - 17:05 Discussion

Session 4B: Best abstracts – Clinical science

Time: Thursday 15:40 - 17:05
Chairs: Nicholas Simon Reed, GBR / Christos Toumpanakis, GBR /
15:40 - 15:47 Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)
Siren Morken, NOR /
15:47 - 15:52 Discussion
15:52 - 15:59 Treatment response and survival according to molecular alterations in 229 patients with high-grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP-NEN)
Hege Elvebakken, NOR /
15:59 - 16:04 Discussion
16:04 - 16:11 Belzutifan, an oral hypoxia-inducible factor 2α inhibitor, for Von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors
Tobias Else, USA /
16:11 - 16:16 Discussion
16:16 - 16:23 Safety of Lanreotide Autogel 120mg plus Metformin in patients with advanced, well-differentiated gastro-intestinal or lung NETs - A pilot, open-label, prospective study: The MetNET-2 Trial (NCT02823691)
Sara Pusceddu, ITA /
16:23 - 16:28 Discussion
16:28 - 16:35 A phase II single arm trial evaluating the efficacy and safety of Temozolomide for second-line treatment of neuroendocrine carcinomas progressing after first-line platinum-based therapy
Claudia von Arx, ITA /
16:35 - 16:40 Discussion
16:40 - 16:47 Incidence, prevalence and survival of neuroendocrine neoplasia 1995–2018
Benjamin Easton White, GBR /
16:47 - 16:52 Discussion
16:52 - 16:59 Characterisation, prognosis, and treatment of patients with locally advanced or metastatic thymic carcinoid tumor: A retrospective study of the French GTE-ENDOCAN RENATEN and RYTHMIC networks
Sarah Fodil-Cherif, FRA /
16:59 - 17:05 Discussion

Poster session – Clinical science

Time: Thursday 17:05 - 17:35
Chairs: Nicholas Simon Reed, GBR / Christos Toumpanakis, GBR /
17:05 - 17:11 Ascl1 and OTP identify four prognostic groups among atypical carcinoids
Giovanni Centonze, ITA /
17:11 - 17:17 Phase 1 study of Intralesional (IL) rose bengal (PV-10), an investigational autolytic immunotherapy
Timothy Price, AUS /
17:17 - 17:23 Opposite treatment approach in two institutes identifies primary tumor resection to be associated with improved disease specific mortality in patients with stage IV small intestinal neuroendocrine tumors (SI-NET) vs watch-and-wait strategy
Sonja Levy, NED /
17:23 - 17:29 Sex differences in survival of neuroendocrine neoplasia in England 1995 - 2018
Benjamin Easton White, GBR /
17:29 - 17:35 PRESTO 2: An international patient survey to evaluate impact of injection and delivery system on local pain when administering somatostatin analogue (SSA) therapy
Dermot O'Toole, IRL /

Poster session – Basic science

Time: Thursday 17:05 - 17:35
Chairs: Aurel Perren, SUI / Anguraj Sadanandam, GBR /
17:05 - 17:11 Exploring the interplay between chromatin-remodeling genes and the regulation of alternative splicing and RNA biology in lung neuroendocrine neoplasms
Antonio Agraz-Doblas, ESP /
17:11 - 17:17 Molecular characterization of the splicing machinery in pheochromocytomas and paragangliomas unveils a marked dysregulation with instructive potential
Maria Trinidad Moreno-Montilla, ESP /
17:17 - 17:23 The chromosome 18 loss of heterozygosity axis of small intestinal neuroendocrine tumors
Scott Waterfield, GBR /
17:23 - 17:29 Development and verification of a new monoclonal OTP specific antibody for pulmonary carcinoid diagnostics
Ernst-Jan Speel, NED /
17:29 - 17:35 The first circulating tumor cell-derived explant (CDX) model of a Merkel cell carcinoma
Melissa Frizziero, GBR /

Coffee break

Time: Thursday 17:35 - 18:15

ENETS General Assembly (Members only)

Time: Thursday 18:15 - 19:30

Friday, 11 March 2022

Satellite symposium – Industry-sponsored

Time: Friday 07:30 - 08:30

Session 5: Systemic treatment of advanced NETs – Have we made any progress?

Time: Friday 08:30 - 10:25
Chairs: Nicola Fazio, ITA / Marianne Pavel, GER /
08:30 - 08:50 What’s changing our practice?
Emily Bergsland, USA /
08:50 - 08:55 Discussion
08:55 - 09:05 Randomized open label phase III study comparing the efficacy and safety of Everolimus followed by chemotherapy with Streptozotocin-5FU upon progression or the reverse sequence in advanced progressive panNETs: The SEQTOR study (GETNE 1206)
Ramon Salazar, ESP /
09:05 - 09:10 Discussion
Debate on the optimal sequencing of systemic therapy in advanced Pancreatic NETs – What’s the preferred option upon progression after one year of SSA therapy? (09:10 - 10:25)
09:10 - 09:20 Clinical case presentation
Nicola Fazio, ITA /
09:20 - 09:25 Discussion
09:25 - 09:33 Defending everolimus
Ramon Salazar, ESP /
09:33 - 09:41 Defending PRRT
Tessa Brabander, NED /
09:41 - 09:49 Defending angiogenesis inhibitors
Angela Lamarca, GBR /
09:49 - 09:57 Defending chemotherapy
Michel Ducreux, FRA /
09:57 - 10:05 Defending high dose SSA
Anja Rinke, GER /
10:05 - 10:25 Panel discussion

Nurse symposium

Time: Friday 08:45 - 10:25
Chairs: Wanda Geilvoet, NED /
08:45 - 08:50 Welcome
Wanda Geilvoet, NED /
Latest update in care for NET patients (08:50 - 09:55)

Chairs: Wanda Geilvoet, NED & Lise Munk Plum, DEN

08:50 - 09:05 'Assessing the landscape' - Patient experience
Wendy Martin, GBR /
09:05 - 09:20 'Towing the line' - Dietitian guidelines
Mette Borre, DEN /
09:20 - 09:35 'Mind the Gap!' - Immunotherapy trials
Jenny Falkerby, SWE /
09:35 - 09:45 Global NET patient info pack
Teodora Kolarova, BUL /
09:45 - 09:55 Discussion
Abstract session (09:55 - 10:20)

Chairs: Wanda Geilvoet, NED & Wendy Martin, GBR

09:55 - 10:05 Abstract presentation: Addressing professional development needs in neuroendocrine cancer nursing
Nicola Jervis, GBR /
10:05 - 10:15 Abstract presentation: The role of the NET clinical nurse specialist in managing carcinoid heart disease patients: Optimising patient care
Stacey Smith, GBR /
10:15 - 10:20 Discussion
10:20 - 10:25 Closing comments
Wanda Geilvoet, NED /

Coffee break

Time: Friday 10:25 - 10:55

Session 6: New developments in the management of high-grade NEC

Time: Friday 10:55 - 12:10
Chairs: Anna Koumarianou, GRE / Juan Valle, GBR /
10:55 - 11:10 Impact of primary tumor site on treatment choices
Nitya Raj, USA /
11:10 - 11:15 Discussion
11:15 - 11:30 Do recent results from clinical trials change the clinical management?
Rocio Garcia-Carbonero, ESP /
11:30 - 11:35 Discussion
11:35 - 11:50 Current clinical trial landscape in NEC and future perspectives
Rachel Riechelmann, BRA /
11:50 - 11:55 Discussion
11:55 - 12:05 NICENEC phase 2 trial of nivolumab and platinum-doublet chemotherapy in untreated advanced G3 NENs of gastroenteropancreatic or unknown origin: Efficacy by differentiation, KI67 index and primary tumor site
María del Carmen Riesco-Martinez, ESP /
12:05 - 12:10 Discussion

ENETS / INCA symposium - Advocacy approach to the diagnostic dilemma in NENs

Time: Friday 10:55 - 12:15
Chairs: Catherine Bouvier, GBR / Marianne Pavel, GER /
10:55 - 10:58 Welcome and introductions from ENETS/INCA
Catherine Bouvier, GBR / Marianne Pavel, GER /
10:58 - 11:03 Detecting NENs: The patient story of a general practitioner (GP)
David B., GBR /
11:03 - 11:28 Multidisciplinary team panel discussion
Martyn Caplin, GBR / Sugandha Dureja, IND / Stefan Stättner, AUT / Eva Tiensuu Janson, SWE / Marie-Louise van Velthuysen, NED /
11:28 - 11:35 'Think NENs' Educational Program for GPs
Mark McDonnell, IRL /
Advocacy and medical education best practice examples (11:35 - 11:50)
11:35 - 11:40 Overview of global best practice examples in advocacy
Simone Leyden, AUS /
11:40 - 11:45 ENETS Educational Programme
Eric Baudin, FRA /
11:45 - 11:50 The search for new biomarkers
Enrique Grande, ESP /
11:50 - 11:55 Raising awareness on NENs on a global scale
Teodora Kolarova, BUL /
11:55 - 12:10 Q&A Discussion
12:10 - 12:15 Wrap-up and closing comments
Mark McDonnell, IRL / Marianne Pavel, GER /

Lunch break

Time: Friday 12:30 - 14:00

Satellite symposium – Industry-sponsored

Time: Friday 12:30 - 14:00

Session 7: Pheochromocytoma, paraganglioma and medullary thyroid carcinoma

Time: Friday 14:00 - 15:00
Chairs: Beata Kos-Kudła, POL / Anders Sundin, SWE /
14:00 - 14:15 Biomarkers and functional imaging of pheochromocytoma / paraganglioma and medullary thyroid cancer – Which modality should be used?
Antongiulio Faggiano, ITA /
14:15 - 14:20 Discussion
14:20 - 14:35 Personalized treatment in advanced medullary thyroid carcinoma
Daria Handkiewicz-Junak, POL /
14:35 - 14:40 Discussion
14:40 - 14:55 Personalized treatment in advanced paragangliomas and pheochromocytomas
Simona Glasberg, ISR /
14:55 - 15:00 Discussion

Life Achievement Award

Time: Friday 15:00 - 15:20
15:00 - 15:10 Laudatio
Marianne Pavel, GER /
15:10 - 15:20 Recipient and keynote address
Günter Klöppel, GER /

Awards ceremony

Time: Friday 15:20 - 15:35

Session 8: What’s new in 2021/2022?

Time: Friday 15:35 - 16:20
15:35 - 16:05 Best abstract resumé - Clinical science
Robert T. Jensen, USA /
16:05 - 16:20 Review of basic science
Eva Tiensuu Janson, SWE /

Welcome the new ENETS Chair & Closing comments

Time: Friday 16:20 - 16:30
Marianne Pavel, GER / Eva Tiensuu Janson, SWE /